1887

Abstract

Cholestatic hepatitis C (CHC) is a severe form of hepatitis C virus (HCV) infection recurrence that leads to high graft loss rates early after liver transplantation (LT). To investigate the pathogenic mechanisms of CHC, we analysed HCV quasispecies in CHC patients compared to a control group (mild hepatitis C recurrence) by deep pyrosequencing. At the time of LT, NS5B quasispecies complexity was similar between the two groups but, after LT, it decreased more sharply in CHC patients than in the control group. Interestingly, the major variant before LT propagated efficiently and remained as the dominant sequence after LT in 62 % of CHC patients versus 11 % of controls (P=0.031). Sequence analysis of the complete non-structural region in a limited number of patients revealed a potential 12 aa signature specific to the CHC group. These data suggest that intrinsic molecular determinants in the circulating HCV quasispecies may provide a fitness advantage, contributing to the development of CHC.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001175
2018-11-19
2019-10-14
Loading full text...

Full text loading...

References

  1. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008;14:S36–S44 [CrossRef][PubMed]
    [Google Scholar]
  2. Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012;142:1373–1383 [CrossRef][PubMed]
    [Google Scholar]
  3. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013;58:1028–1041 [CrossRef][PubMed]
    [Google Scholar]
  4. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010;16:1228–1235 [CrossRef][PubMed]
    [Google Scholar]
  5. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007;13:219–226 [CrossRef][PubMed]
    [Google Scholar]
  6. Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol 2008;1:396–402[PubMed]
    [Google Scholar]
  7. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1–S9 [CrossRef][PubMed]
    [Google Scholar]
  8. Forns X, Mutimer D, Manns M, Reddy KR, Everson GT et al. P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. J Hepatol 2015;62:S623 [CrossRef]
    [Google Scholar]
  9. Wadhawan M, Vij V, Makki K, Bansal N, Kumar A. Early acute severe HCV recurrence after transplantation: from universal mortality to cure. J Clin Exp Hepatol 2017;7:28–32 [CrossRef][PubMed]
    [Google Scholar]
  10. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685–697 [CrossRef][PubMed]
    [Google Scholar]
  11. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015;13:1993–2001 [CrossRef][PubMed]
    [Google Scholar]
  12. Issa D, Eghtesad B, Zein NN, Yerian L, Cruise M et al. Sofosbuvir and simeprevir for the treatment of recurrent hepatitis C with fibrosing cholestatic hepatitis after liver transplantation. Int J Organ Transplant Med 2016;7:38–45[PubMed]
    [Google Scholar]
  13. Forns X, Charlton M, Denning J, Mchutchison JG, Symonds WT et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015;61:1485–1494 [CrossRef][PubMed]
    [Google Scholar]
  14. Mccaughan GW, Bowen DG. Pathogenesis of cholestatic hepatitis C. J Hepatol 2011;54:392–394 [CrossRef][PubMed]
    [Google Scholar]
  15. Ramírez S, Pérez-del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl 2008;14:S27–S35 [CrossRef][PubMed]
    [Google Scholar]
  16. Lim HL, Lau GK, Davis GL, Dolson DJ, Lau JY. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology 1994;106:248–251 [CrossRef][PubMed]
    [Google Scholar]
  17. Zylberberg H, Carnot F, Mamzer MF, Blancho G, Legendre C et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997;63:158–160 [CrossRef][PubMed]
    [Google Scholar]
  18. Delgado J, Muñoz de Bustillo E, Ibarrola C, Colina F, Morales JM et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor?. J Heart Lung Transplant 1999;18:607–610 [CrossRef][PubMed]
    [Google Scholar]
  19. Demetris AJ. Evolution of hepatitis C virus in liver allografts. Liver Transpl 2009;15 Suppl 2:S35–S41 [CrossRef][PubMed]
    [Google Scholar]
  20. Giard JM, Terrault NA. Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival. Clin Gastroenterol Hepatol 2015;13:2002–2004 [CrossRef][PubMed]
    [Google Scholar]
  21. Feliu A, Gay E, García-Retortillo M, Saiz JC, Forns X. Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl 2004;10:1131–1139 [CrossRef][PubMed]
    [Google Scholar]
  22. Ramirez S, Perez-del-Pulgar S, Carrion JA, Costa J, Gonzalez P et al. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant 2009;9:1591–1601 [CrossRef][PubMed]
    [Google Scholar]
  23. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999;30:1513–1520 [CrossRef][PubMed]
    [Google Scholar]
  24. Sullivan DG, Wilson JJ, Carithers RL, Perkins JD, Gretch DR. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998;72:10036–10043[PubMed]
    [Google Scholar]
  25. Sánchez-Fueyo A, Giménez-Barcons M, Puig-Basagoiti F, Rimola A, Sánchez-Tapias JM et al. Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. J Med Virol 2001;65:266–275 [CrossRef][PubMed]
    [Google Scholar]
  26. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL, Perkins JD et al. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996;70:7622–7631[PubMed]
    [Google Scholar]
  27. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995;22:112–114 [CrossRef][PubMed]
    [Google Scholar]
  28. Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK et al. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl 2013;19:78–88 [CrossRef][PubMed]
    [Google Scholar]
  29. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001;7:1064–1070 [CrossRef][PubMed]
    [Google Scholar]
  30. Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002;8:123–131 [CrossRef][PubMed]
    [Google Scholar]
  31. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132–142 [CrossRef][PubMed]
    [Google Scholar]
  32. Quer J, Gregori J, Rodríguez-Frias F, Buti M, Madejon A et al. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. J Clin Microbiol 2015;53:219–226 [CrossRef][PubMed]
    [Google Scholar]
  33. Pérez-del-Pulgar S, Gregori J, Rodríguez-Frías F, González P, García-Cehic D et al. Quasispecies dynamics in hepatitis C liver transplant recipients receiving grafts from hepatitis C virus infected donors. J Gen Virol 2015;96:3493–3498 [CrossRef][PubMed]
    [Google Scholar]
  34. Gregori J, Esteban JI, Cubero M, Garcia-Cehic D, Perales C et al. Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants. PLoS One 2013;8:e83361 [CrossRef][PubMed]
    [Google Scholar]
  35. Gregori J, Salicrú M, Domingo E, Sanchez A, Esteban JI et al. Inference with viral quasispecies diversity indices: clonal and NGS approaches. Bioinformatics 2014;30:1104–1111 [CrossRef][PubMed]
    [Google Scholar]
  36. Korber B, Myers G. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses 1992;8:1549–1560 [CrossRef][PubMed]
    [Google Scholar]
  37. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44:717–722 [CrossRef][PubMed]
    [Google Scholar]
  38. Doughty AL, Spencer JD, Cossart YE, Mccaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998;4:15–21 [CrossRef][PubMed]
    [Google Scholar]
  39. Hanouneh IA, Zein NN, Askar M, Lopez R, John B. Interleukin-28B polymorphisms are associated with fibrosing cholestatic hepatitis in recurrent hepatitis C after liver transplantation. Clin Transplant 2012;26:E335E336 [CrossRef][PubMed]
    [Google Scholar]
  40. Massaguer A, Ramírez S, Carrión JA, González P, Sánchez-Tapias JM et al. Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. Am J Transplant 2007;7:2172–2179 [CrossRef][PubMed]
    [Google Scholar]
  41. Martell M, Esteban JI, Quer J, Vargas V, Esteban R et al. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol 1994;68:3425–3436[PubMed]
    [Google Scholar]
  42. Yun Z, Barkholt L, Sönnerborg A. Dynamic analysis of hepatitis C virus polymorphism in patients with orthotopic liver transplantation. Transplantation 1997;64:170–172 [CrossRef][PubMed]
    [Google Scholar]
  43. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999;117:926–932 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001175
Loading
/content/journal/jgv/10.1099/jgv.0.001175
Loading

Data & Media loading...

Supplementary File 1

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error